Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601950 · ClinicalTrials.gov registry record · Phase 2
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
A Phase 2 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT02601950: Completed Phase 2 study, sponsored by Epizyme.
NCT02601950 is a Phase 2 study that has completed, run by Epizyme. The registered enrollment target is 267 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02601950, a Phase 2 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body. Part 1 of this trial will study the safety and the level that adverse effects of the study drug tazemetostat in combination with doxorubicin (current front line treatment) can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug plus doxorubicin versus doxorubicin plus placebo (dummy treatment).
Primary Outcome
ORR was defined as percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) based on the investigator review from start of treatment until progressive disease (PD) or start of subsequent anti-cancer therapy or cancer-related surgery, whichever was earlier, as per response assessment in neuro-oncology (RANO) criteria for primary brain tumors or response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria for all other solid tumors. CR w
Interventions
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2024-02-26 |
| Phase | Phase 2 |
What the finished NCT02601950 record still lists
NCT02601950 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 1 intervention - of which Tazemetostat is the first listed.
NCT02601950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02601950 about?
NCT02601950 is a clinical study titled "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma". This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body...
What is the current status of trial NCT02601950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2015-12-22. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT02601950?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT02601950?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02601950's enrollment target sits among peer trials
267 209th of 2000 higher than 1,792 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI